Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance - Wikidata - wikimedia - TriplyDB

Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance

Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance

http://www.wikidata.org/entity/Q26795554

about

Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review.Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers.

P2860

Q37669293-4E712888-AEEE-46FF-8EF5-F7FCB9D3DABD Q37742180-A8A54CBE-6DFB-4143-9588-0C44D76F3C33 Q38737784-2B972BCF-02ED-4060-9CB9-3D3E67839207 Q38956073-E37068E5-678B-4844-8698-3958A5C980DB

P2860

Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance

http://www.wikidata.org/entity/Q26795554

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Skeletal adverse effects with ...... to date and clinical guidance

@ast

Skeletal adverse effects with ...... to date and clinical guidance

@en

Skeletal adverse effects with ...... to date and clinical guidance

@nl

type

label

Skeletal adverse effects with ...... to date and clinical guidance

@ast

Skeletal adverse effects with ...... to date and clinical guidance

@en

Skeletal adverse effects with ...... to date and clinical guidance

@nl

prefLabel

Skeletal adverse effects with ...... to date and clinical guidance

@ast

Skeletal adverse effects with ...... to date and clinical guidance

@en

Skeletal adverse effects with ...... to date and clinical guidance

@nl

P1433

Q26795554-41CC3AFE-5D96-452C-9A1E-1DF2421A97A4

P1476

Q26795554-B3762BE5-5C2B-49DA-8F9C-2F95BCA731D7

P2093

Q26795554-022EAE45-C988-460B-B104-52E6283BF2DE

Q26795554-0EC969CE-E883-4A7D-A803-397B87AAB248

Q26795554-63461D60-74EC-4A62-983A-3514D41945FF

Q26795554-7B03541D-C7B4-42E0-8BAF-2CFF05A7C1AB

Q26795554-CD7F7935-207B-4084-8872-D119C500B4E2

P2860

Q26795554-069C9D81-2B2B-4855-B43F-406A5897292A

Q26795554-0BB655C8-3D9C-40CB-972F-6561FFFC0271

Q26795554-2178CBCA-06DD-46D3-AA67-C7C1BF383E61

Q26795554-411131E6-D8CA-47AA-BDF3-692C152B906D

Q26795554-59AA4512-F873-4048-A6C0-38FF1D916790

Q26795554-5B866ECB-B984-495F-9C04-F5DBDAC1FA10

Q26795554-62E45C2F-7640-43B7-95F0-DE78E1991D74

Q26795554-68956363-84AC-475C-A5BB-2E4EB8CE78BA

Q26795554-85D80709-7B6D-407E-8793-C1B4AA1A5926

Q26795554-8D35CC27-3B2A-4F64-8CB7-76C93DC7378C

P304

Q26795554-354B4FDF-E33A-4488-AC18-38A6EE04F9CA

P31

Q26795554-FF2DA46B-F758-4A26-A48F-EF8E7A391922

P356

Q26795554-AD19FB36-B9DC-4D10-B302-4F43B836D89D

P407

Q26795554-BCBD0649-551F-432B-A04B-C7EEEE977EBA

P433

Q26795554-622596ED-75F8-4DE3-9E71-4248076AE3C5

P478

Q26795554-2C4B8291-F17C-4583-844D-795D74F67227

P50

Q26795554-249ACE52-81F7-4CA5-B4DC-32A18A610FE1

Q26795554-49B26788-C39C-4D82-AFB5-54B4F1CD8C2D

Q26795554-64EBB24F-6A97-4861-AE0A-C43873AE6CAF

Q26795554-91262B50-4CE8-40CB-9B9B-D58A102F99D5

P577

Q26795554-0B31DD89-7267-4DA2-A60E-45FB78818973

P698

Q26795554-E229B881-16E7-486B-AC13-FBDCB6A26A8B

P932

Q26795554-5033BFC3-2549-431B-A77E-807C1D5167B0

P356

1758834015598536

P1433

Therapeutic advances in medical oncology

P1476

Skeletal adverse effects with ...... to date and clinical guidance

@en

P2093

Ignasi Tusquets

http://www.w3.org/2001/XMLSchema#string

Laia Garrigos

http://www.w3.org/2001/XMLSchema#string

Maria Rodriguez Sanz

http://www.w3.org/2001/XMLSchema#string

Sonia Servitja

http://www.w3.org/2001/XMLSchema#string

Tamara Martos

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes.

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.

Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain.

Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials.

Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial.

COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy.

P304

291-296

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834015598536

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Daniel Prieto-Alhambra

Natalia Garcia-Giralt

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26327926

http://www.w3.org/2001/XMLSchema#string

P932

4543856

http://www.w3.org/2001/XMLSchema#string